Preventive HIV vaccine acceptability and behavioral risk compensation among high-risk men who have sex with men and transgenders in Thailand

Vaccine

Volumn 28, Issue 4, 2010, Pages 958-964

  Newman, Peter A ^a   Roungprakhon, Surachet ^b   Tepjan, Suchon ^c   Yim, Suzy ^a  

^a UNIVERSITY OF TORONTO   (Canada)

^b KING MONGKUT'S UNIVERSITY OF TECHNOLOGY NORTH BANGKOK   (Thailand)

^c CHIANG MAI UNIVERSITY   (Thailand)

Author keywords

HIV vaccine; Men who have sex with men; Risk compensation; Thailand; Vaccine induced seropositivity

Indexed keywords

HUMAN IMMUNODEFICIENCY VIRUS VACCINE;

ARTICLE; HEALTH SURVEY; HIGH RISK POPULATION; HUMAN; INTERVIEW; MALE HOMOSEXUAL; PRIORITY JOURNAL; QUESTIONNAIRE; RISK ASSESSMENT; TRANSSEXUALISM;

ADOLESCENT; ADULT; AIDS VACCINES; HIV INFECTIONS; HOMOSEXUALITY, MALE; HUMANS; MALE; PATIENT ACCEPTANCE OF HEALTH CARE; QUESTIONNAIRES; RISK-TAKING; THAILAND; TRANSSEXUALISM; YOUNG ADULT;

EID: 73949147869     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2009.10.142     Document Type: Article

References (58)

1. Rerks-Ngarm S., Pitisuttithum P., Nitayaphan S., Kaewkungwal J., Chiu J., Paris R., et al. Vaccination with ALVAC and AIDSVAX to prevent HIV-1 Infection in Thailand. New Engl J Med (2009) 10.1056/NEJMoa0908492 [Epub ahead of print].
2. Corey L., McElrath M.J., and Kublin J.G. Post-step modification for research on HIV vaccines. AIDS 23 1 (2009) 3-8
3. Mills E., Cooper C., Guyatt G., Gilchrist A., Rachlis B., Sulway C., et al. Barriers to participating in an HIV vaccine trial: a systematic review. AIDS 18 (2004) 2235-2242
4. Dhalla S., Nelson K.E., Singer J., and Poole G. HIV vaccine preparedness studies in the non-organization for economic co-operation and development (non-OECD) countries. AIDS Care 21 3 (2009) 335-348
5. Newman P.A., Daley A., Halpenny R., and Loutfy M. Community heroes or 'high-risk' pariahs? Reasons for declining to enroll in an HIV vaccine trial. Vaccine 26 8 (2008) 1091-1097
6. Newman P.A., Duan N., Rudy E., Roberts K.J., and Swendeman D. Post-trial HIV vaccine adoption: concerns, motivators and intentions among persons at risk for HIV. J Acquir Immune Defic Syndr 37 3 (2004) 1393-1403
7. Newman P.A., Duan N., Lee S.-J., Rudy E., Seiden D., Kakinami L., et al. HIV vaccine acceptability among communities at risk: the impact of vaccine characteristics. Vaccine 24 12 (2006) 2094-2101
8. Newman P.A., Lee S.-J., Duan N., Rudy E., Nakazono T.K., Boscardin J., et al. Preventive HIV vaccine acceptability and risk compensation among a random sample of high-risk adults in Los Angeles (L.A. VOICES). Health Serv Res 44 6 (2009) 2167-2179
9. Zimet G.D., Blythe M.J., and Fortenberry J.D. Vaccine characteristics and acceptability of HIV immunization among adolescents. Int J STD AIDS 11 3 (2000) 143-149
10. Liau A., and Zimet G.D. The acceptability of HIV immunization: examining vaccine characteristics as determining factors. AIDS Care 13 (2001) 643-650
11. Institute of Medicine. Calling the shots: immunization finance policies and practices (2000), National Academy Press, Washington
12. Schutten M., de Wit J.B.F., and van Steenbergen J.E. Why do gay men want to be vaccinated against hepatitis B? An assessment of psychosocial determinants of vaccination intention. Int J STD AIDS 13 (2002) 86-90
13. Medical Officer of Health (MOH) Toronto. Human papillomavirus (HPV) vaccination program update. Available from: http://www.toronto.ca/legdocs/mmis/2008/hl/bgrd/backgroundfile-15460.pdf; 2008 [04.09.08].
14. Davies P., Chapman S., and Leask J. Antivaccination activists on the world wide web. Arch Dis Child 87 (2002) 22-25 10.1136/adc.87.1.22
15. Jacobson R.M., Targonski P.V., and Poland G.A. A taxonomy of reasoning flaws in the anti-vaccine movement. Vaccine 25 16 (2007) 3146-3152
16. Esparza J., Chang M.L., Widdus R., Madrid Y., Walker N., and Ghys P.D. Estimation of needs and probable uptake for HIV/AIDS preventive vaccines based on possible policies and likely acceptance (a WHO/UNAIDS/IAVI study). Vaccine 21 17-18 (2003) 2032-2041
17. Esparza J., Osmanov S., Pattou-Markovic C., Touré C., Chang M.L., and Nixon S. Past, present and future HIV vaccine trials in developing countries. Vaccine 20 (2002) 1897-1898
18. UNAIDS. 2007 AIDS epidemic update. Available from: http://data.unaids.org/pub/EPISlides/2007/2007_epiupdate_en.pdf [December 2007].
19. Baral S., Sifakis F., Cleghorn F., and Beyrer C. Elevated risk for HIV infection among men who have sex with men in low- and middle-income countries 2000-2006: a systematic review. PloS Med 4 (2007) 1901-1911
20. van Griensven F., Thanprasertsuk S., Jommaroeng R., Mansergh G., Naorat S., Jenkins R.A., et al. Evidence of a previously undocumented epidemic of HIV infection among men who have sex with men in Bangkok, Thailand. AIDS 19 (2005) 521-526
21. AVERT. South East Asian HIV and AIDS statistics. Available from: http://www.avert.org/aidssoutheastasia.htm; 2009 [04.06.09].
22. Centers for Disease Control and Prevention. HIV prevalence among populations of men who have sex with men-Thailand, 2003 and 2005. MMWR Morb Mortal Wkly Rep 55 31 (2006) 844-848
23. Gouws E., White P.J., Stover J., and Brown T. Short term estimates of adult HIV incidence by mode of transmission: Kenya and Thailand as examples. Sex Transm Infect 82 (2006) iii51-iii55
24. Pliplat T., Kladsawas K., van Griensven F., and Wimonsate W. Results of the HIV surveillance among men who have sex with men (MSM) in Bangkok, Chiangmai and Phuket. Proceedings for the Department of Disease Control Annual Conference, Ministry of Public Health. Presented at the Department of Disease Control Annual Conference. Bi-Tech Convention Centre (in Thai); Bangkok (2008)
25. Phanuphak P., Locharernkul C., Panmuong W., and Wilde H. A report of three cases of AIDS in Thailand. Asian Pac J Allergy Immunol 3 (1985) 195-199
26. Lee S.J., Brooks R., Newman P.A., Seiden D., Sangthong R., and Duan N. HIV vaccine acceptability among immigrant Thai residents in Los Angeles: a mixed-methods approach. AIDS Care 20 10 (2008) 1161-1168
27. Tangcharoensathien V., Phoolcharoen W., Pitayarangsarit S., Khongsin S., Kasemsup V., Tantivess S., et al. The potential demand for an AIDS vaccine in Thailand. Health Policy 57 2 (2001) 111-139
28. Suraratdecha C., Ainsworth M., Tangcharoensathien V., and Whittington D. The private demand for an AIDS vaccine in Thailand. Health Policy 71 (2005) 271-287
29. Ackers M.L., Parekh B., Evans T.G., Berman P., Phillips S., Allen M., et al. Human immunodeficiency virus (HIV) seropositivity among uninfected HIV vaccine recipients. J Infect Dis 187 6 (2003) 879-886
30. Newman P.A., Duan N., Rudy E.T., and Anton P.A. Challenges for HIV vaccine dissemination and clinical trial recruitment: if we build it, will they come?. AIDS Patient Care STDS 18 12 (2004) 691-701
31. Silbermann B., Tod M., Desaint C., Pialoux G., Petitprez K., Slama L., et al. Short communication: long-term persistence of vaccine-induced HIV seropositivity among healthy volunteers. AIDS Res Hum Retroviruses 24 11 (2008) 1445-1448
32. Blower S., Schwartz E.J., and Mills J. Forecasting the future of HIV epidemics: the impact of antiretroviral therapies and imperfect vaccines. AIDS Rev 5 (2003) 113-125
33. Gust D.A., Wiegand R.E., Para M., Chen R.T., and Bartholow B.N. HIV testing outside of the study among men who have sex with men participating in an HIV vaccine efficacy trial. J Acquir Immune Defic Syndr 52 2 (2009) 294-298
34. Kajubi P., Kamya M.R., Kamya S., Chen S., McFarland W., and Hearst N. Increasing condom use without reducing HIV risk: results of a controlled community trial in Uganda. J Acquir Immune Defic Syndr 40 1 (2005) 77-82
35. Crepaz N., Hart T.A., and Marks G. Highly active antiretroviral therapy and sexual risk behavior: a meta-analytic review. JAMA 292 2 (2004) 224-236
36. Richens J., Imrie J., and Copas A. Condoms and seat belts: the parallels and the lessons. Lancet 355 (2000) 400-403
37. Tashakkori A., and Teddlie C. Foundations of mixed methods research: integrating quantitative and qualitative approaches in the social and behavioral sciences (2009), Sage Publications, Thousand Oaks, CA
38. NVivo 7. QSR International Pty Ltd., Australia. Available from: http://www.qsrinternational.com/FileResourceHandler.ashx/RelatedDocuments/DocumentFile/480/NVivo7_Brochure.pdf; February 2006
39. Charmaz K. Constructing grounded theory: a practical guide through qualitative analysis (2006), Sage Publications, Thousand Oaks, CA
40. Corbin J., and Strauss A. Basics of qualitative research. 3rd ed. (2008), Sage Publications, Thousand Oaks, CA
41. Creswell J., and Plano Clark V. Designing and conducting mixed methods research (2007), Sage Publications, Thousand Oaks, CA
42. Frankel M.R., Shapiro M.F., Duan N., Morton S.C., Berry S.H., Brown J.A., et al. National probability samples in studies of low-prevalence diseases. Part II: designing and implementing the HIV cost and services utilization study sample. Health Serv Res 34 5.1 (1999) 969-992
43. Jenkins C., Pramoj na Ayutthaya P., and Hunter A. Katoey in Thailand: HIV/AIDS and life opportunities (2005), Futures Group, POLICY Project, Washington, DC 31 pp. [USAID Contract No. HRN-C-00-00-00006-00]
44. Microsoft. Microsoft Office 2007 Access and Visual Basic. Seattle, WA. Available from: http://office.microsoft.com/en-us/access/default.aspx and http://msdn.microsoft.com/en-us/vbasic/default.aspx; 2007.
45. Ryan M., McIntosh E., and Shackley P. Methodological issues in the application of conjoint analysis in health care. Health Econ 7 4 (1998) 373-378
46. SPSS for Windows, Rel. 17.0. Chicago: SPSS Inc.; 2008.
47. Trials Database. IAVI Report 2009. Available from: http://www.iavireport.org/trials-db/Pages/default.aspx; 2009 [05.06.09].
48. Jenkins R.A., Temoshok L.R., and Virochsiri K. Incentives and disincentives to participate in prophylactic HIV vaccine research. J Acquir Immune Defic Syndr Hum Retrovirol 9 1 (1995) 36-42
49. Jenkins R.A., Thapinta D., Morgan P.A., Wongkamhaeng S., and Sornsathapornkul P. Behavioral and social issues among volunteers in a preventive HIV vaccine trial in Thailand. J Acquir Immune Defic Syndr 40 5 (2006) 592-599
50. Fuchs J., Durham M., McLellan-Lemal E., Vittinghoff E., Colfax G., Gurwith M., et al. Negative social impacts among volunteers in an HIV vaccine efficacy trial. J Acquir Immune Defic Syndr 46 3 (2007) 362-368
51. Bechtel G.A., and Apakupakul N. AIDS in southern Thailand: stories of krengjai and social connections. J Adv Nurs 29 (1999) 471-475
52. Newman P.A., Seiden D., Roberts K., and Duan N. A small dose of HIV? HIV vaccine mental models and risk communication. Health Educ Behav 36 (2009) 321-333
53. National Economic and Social Development Board. Office of the National Economic and Social Development Board, National Income of Thailand. Available from: http://www.nesdb.go.th/econSocial/macro/gdp_data/reportagdp.asp?heading_id=64; 2008.
54. Hecht R., and Suraratdecha C. Estimating the demand for a preventive HIV vaccine: why we need to do better. PLoS Med 3 10 (2006) 1728-1732
55. Hedlund J. Risky business: safety regulations, risk compensation, and individual behavior. Injury Prev 6 (2000) 82-90
56. Newman P.A., Duan N., Rudy E., and Roberts K.J. HIV risk and prevention in a post-vaccine context. Vaccine 22 15-16 (2004) 1954-1963
57. Khurana S., Needham J., Park S., Bonnie M., Michael P.B., George N., et al. Novel approach for differential diagnosis of HIV infections in the face of vaccine-generated antibodies. J Acquir Immune Defic Syndr 43 3 (2006) 304-312
58. Hay J.W. Conjoint analysis in pharmaceutical research. J Manag Care Pharm 8 3 (2002) 206-208